- Home
- RSVR vs ADCT Comparison
RSVR vs ADCT Comparison
Compare RSVR & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RSVR | ADCT |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.2M | 454.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RSVR | ADCT |
|---|---|---|
| Price | $7.53 | $4.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $11.50 | $7.60 |
| AVG Volume (30 Days) | 68.7K | ★ 743.6K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $166,320,844.00 | $75,209,000.00 |
| Revenue This Year | $7.17 | $11.78 |
| Revenue Next Year | $5.00 | $4.83 |
| P/E Ratio | $51.80 | ★ N/A |
| Revenue Growth | ★ 11.17 | 6.35 |
| 52 Week Low | $6.56 | $1.05 |
| 52 Week High | $9.83 | $4.80 |
Technical Indicators
Market Signals| Indicator | RSVR | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 56.64 |
| Support Level | $7.19 | $3.95 |
| Resistance Level | $7.49 | $4.45 |
| Average True Range (ATR) | 0.19 | 0.26 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 77.89 | 76.72 |
Price Performance
Historical ComparisonAbout RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. It operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the Music Publishing segment.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).